Document is current
Any future updates will be listed below
-
Authors
Phung, Kim
McAdam, Laura
Ma, Jinhui
McMillan, Hugh J.
Jackowski, Stefan
Scharke, Maya
Matzinger, Mary-Ann
Shenouda, Nazih
Koujok, Khaldoun
Jaremko, Jacob L.
Smit, Kevin
Walker, Scott
Hartigan, Colleen
Khan, Nasrin
Konji, Victor N.
MacLeay, Lynn
Page, Marika
Sykes, Elizabeth
Robinson, Marie-Eve
Alos, Nathalie
Cummings, Elizabeth A.
Ho, Josephine
Sbrocchi, Anne Marie
Stein, Robert
Saleh, David
Craven, B. Catharine
Dang, Utkarsh J.
Siminoski, Kerry
Rauch, Frank
Ward, Leanne M. https://orcid.org/0000-0003-1557-9185
-
Funding
Funding for this research was provided by:
Physicians' Services Incorporated Foundation (14-03)
Parent Project Muscular Dystrophy
Defeat Duchenne Canada
Canadian Institutes of Health Research (CIHR FRN 64285)
- License Information
-
More Information
Article History
Received: 13 June 2022
Accepted: 13 October 2022
First Online: 7 November 2022
Declarations
:
: None of the authors have conflicts of interest related to this observational study. Unrelated to the study, some of the authors report the following potential conflicts of interest: NA has participated in clinical trials with Amgen and Novartis. MER has received a study grant from Ascendis Biopharma, and consultancy fees from Ipsen Biopharmaceuticals and Ultragenyx, with funds to her institution. HJM has participated in clinical trials with Roche, PTC Therapeutics, ReveraGen, Catabasis, Novartis and Sarepta, been a consultant for Novartis Gene Therapies and received research support from Roche. UJD has been a consultant to, and participated in clinical trials with, ReveraGen Biopharma. LMW has been a consultant to, and participated in clinical trials with, Amgen, Novartis, PTC, ReveraGen, Catabasis, Ipsen, and Ultragenyx, with funds to her institution.
